TipRanks
Advertisement
Advertisement

FDMT Stock Latest News

4D Molecular management to meet with B. Riley
The Fly4D Molecular management to meet with B. Riley
3d ago
FDMT
4D Molecular upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe Fly
4D Molecular upgraded to Overweight from Neutral at Cantor Fitzgerald
6d ago
FDMT
B. Riley views EyePoint study miss as positive for 4D Molecular
PremiumThe Fly
B. Riley views EyePoint study miss as positive for 4D Molecular
1M ago
EYPT
FDMT
4D Molecular reports Q2 EPS ($1.04), consensus ($1.02)
PremiumThe Fly
4D Molecular reports Q2 EPS ($1.04), consensus ($1.02)
1M ago
FDMT
4D Molecular price target lowered to $32 from $33 at Goldman Sachs
PremiumThe Fly
4D Molecular price target lowered to $32 from $33 at Goldman Sachs
1M ago
FDMT
Analyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials
PremiumRatingsAnalyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials
1M ago
FDMT
Roblox downgraded, Quanta Services upgraded: Wall Street’s top analyst calls
Premium
The Fly
Roblox downgraded, Quanta Services upgraded: Wall Street’s top analyst calls
2M ago
IP
BSX
4D Molecular initiated with a Buy at B. Riley
Premium
The Fly
4D Molecular initiated with a Buy at B. Riley
2M ago
LLY
FDMT
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results
PremiumCompany Announcements
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results
2M ago
8K
FDMT
4D-150’s Durable Efficacy and Clean Safety Profile Support Buy Rating and Unchanged $36 Price Target
PremiumRatings
4D-150’s Durable Efficacy and Clean Safety Profile Support Buy Rating and Unchanged $36 Price Target
2M ago
FDMT
4D Molecular Therapeutics Buy Rating Reaffirmed on 4D-150 Pivotal Trial Momentum; Price Target Maintained at $36
PremiumRatings
4D Molecular Therapeutics Buy Rating Reaffirmed on 4D-150 Pivotal Trial Momentum; Price Target Maintained at $36
3M ago
FDMT
4D Molecular Therapeutics Secures $200 Million Loan Facility
PremiumCompany Announcements
4D Molecular Therapeutics Secures $200 Million Loan Facility
3M ago
8K
FDMT
4D Molecular completes enrollment in 4FRONT-2 trial
PremiumThe Fly4D Molecular completes enrollment in 4FRONT-2 trial
3M ago
FDMT
4D Molecular Therapeutics Stockholders Back Directors and Governance
Premium
Company Announcements
4D Molecular Therapeutics Stockholders Back Directors and Governance
3M ago
8K
FDMT
Analyst Reiterates Buy on 4D Molecular Therapeutics as Wet AMD Gene Therapy Advances, Keeps $36 Price Target Unchanged
Premium
Ratings
Analyst Reiterates Buy on 4D Molecular Therapeutics as Wet AMD Gene Therapy Advances, Keeps $36 Price Target Unchanged
4M ago
FDMT
Daniel Giraldo Reiterates Buy on 4D Molecular Therapeutics, Citing Strong 4D-150 Progress and Undervalued Upside vs. $29 Price Target
PremiumRatings
Daniel Giraldo Reiterates Buy on 4D Molecular Therapeutics, Citing Strong 4D-150 Progress and Undervalued Upside vs. $29 Price Target
4M ago
FDMT
4D Molecular price target lowered to $33 from $38 at Goldman Sachs
PremiumThe Fly
4D Molecular price target lowered to $33 from $38 at Goldman Sachs
5M ago
FDMT
4D Molecular files $400M mixed securities shelf
PremiumThe Fly
4D Molecular files $400M mixed securities shelf
5M ago
FDMT
4D Molecular reports Q1 EPS ($1.01), consensus ($1.00)
PremiumThe Fly
4D Molecular reports Q1 EPS ($1.01), consensus ($1.00)
5M ago
FDMT
4D Molecular price target lowered to $23 from $45 at Evercore ISI
PremiumThe Fly4D Molecular price target lowered to $23 from $45 at Evercore ISI
5M ago
FDMT
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role
Premium
Company Announcements
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role
6M ago
8K
FDMT
4D Molecular assumed with a Buy at Jefferies
Premium
The Fly
4D Molecular assumed with a Buy at Jefferies
6M ago
FDMT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >